Mar 30, 2020

FDA approves Roche’s Actemra COVID-19 trial

Posted by in category: biotech/medical

Actemra (tocilizumab) – an interleukin-6 inhibitor – has already been approved in China for the treatment of patients infected with the novel coronavirus disease, who have developed serious lung damage and also have elevated levels of IL-6 in the blood.

It was first cleared by the FDA as a treatment for rheumatoid arthritis and has also subsequently been approved in juvenile idiopathic arthritis, giant cell arteritis and CRS associated with CAR-T cell therapies for cancer.

Plans to initiate trial in early April.

Comments are closed.